Page last updated: 2024-11-04

temozolomide and Depressive Disorder, Major

temozolomide has been researched along with Depressive Disorder, Major in 1 studies

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research Excerpts

ExcerptRelevanceReference
"To illustrate this, we report the case of a 60-year-old male patient confronted with an inoperable glioblastoma multiforme on the splenium of the corpus callosum, of poor prognosis, treated by concomitant radiochemotherapy with temozolomide, who developed psychotic depression with Cotard's syndrome."3.78Cotard's syndrome with glioblastoma multiforme. ( Comet, B; Le Rhun, E; Ramirez, C; Reich, M, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reich, M1
Comet, B1
Le Rhun, E1
Ramirez, C1

Other Studies

1 other study available for temozolomide and Depressive Disorder, Major

ArticleYear
Cotard's syndrome with glioblastoma multiforme.
    Palliative & supportive care, 2012, Volume: 10, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Co

2012